Melatonin effects on bone: Potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures

Journal of Pineal Research

Volumn 56, Issue 2, 2014, Pages 115-125

  Maria, Sifat ^a   Witt Enderby, Paula A ^a  

^a DUQUESNE UNIVERSITY   (United States)

Author keywords

melatonin; menopause; osteoblasts; osteoclasts; osteopenia; osteoporosis; Per2

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; INDOLEAMINE; MELATONIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RALOXIFENE;

BONE CHARACTERISTICS AND FUNCTIONS; BONE TRANSPLANTATION; DENTAL HEALTH; DRUG EFFECT; HUMAN; LIGHT EXPOSURE; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PERIODONTAL DISEASE; REVIEW; SHIFT WORKER; SIGNAL TRANSDUCTION; ANIMAL; BONE DISEASES, METABOLIC; DRUG EFFECTS; MENOPAUSE; MOUSE; OSTEOCLAST; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; BONE DISEASES, METABOLIC; BONE TRANSPLANTATION; HUMANS; MELATONIN; MENOPAUSE; MICE; OSTEOBLASTS; OSTEOCLASTS; RATS;

EID: 84893776367     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12116     Document Type: Review

References (145)

1. Johnell O, Kanis JA,. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-1733. (Pubitemid 44607392)
2. International Osteoporosis Foundation. http://www.iof.org.
3. Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8: 136.
4. National osteoporosis foundation. NOF Encourages Women to Break Free from Osteoporosis in Honor of National Women's Health Week. In http://wwnof.org, 2013.
5. Riggs BL, Melton LJ,. 3RD The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 1995; 17: 505S-511S.
6. National Osteoporosis Foundation. What is osteoporosis?, 2013.
7. van Staa TP, Dennison EM, Leufkens HG, et al. Epidemiology of fractures in England and Wales. Bone 2001; 29: 517-522. (Pubitemid 33124293)
8. Kanis JA,. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-1936. (Pubitemid 34615775)
9. Reginster JY, Burlet N,. Osteoporosis: a still increasing prevalence. Bone 2006; 38: S4-S9. (Pubitemid 43190767)
10. Avis NE, Colvin A, Bromberger JT, et al. Change in health-related quality of life over the menopausal transition in a multiethnic cohort of middle-aged women: Study of Women's Health Across the Nation. Menopause 2009; 16: 860-869.
11. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004; 164: 1108-1112. (Pubitemid 38668990)
12. Pasco JA, Seeman E, Henry MJ, et al. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006; 17: 1404-1409. (Pubitemid 44127328)
13. Loinel S, Hoeksema LJ, Lim LS, et al. Screening for osteoporosis in the adult US population. Am J Prev Med 2009; 36: 366-375.
14. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis, 2013: 9, http://nof.org/hcp/resources/913.
15. NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis, and Therapy. JAMA 2001; 285: 785-795.
16. Gold DT,. Compliance and persistence with osteoporosis medications. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 8th edn., Rosen CJ, ed., John Wiley & Sons, Inc, Ames, 2013.
17. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534. (Pubitemid 38542516)
18. Torres J, Tamimi F, Garcia I, et al. Management of atrophic maxilla in severe osteoporosis treated with bisphosphonates: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 668-672.
19. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011; 305: 783-789.
20. Rutkowski JL,. Combined use of glucocorticoids and bisphosphonates may increase severity of bisphosphonate-related osteonecrosis of the jaw. J Oral Implantol 2011; 37: 505.
21. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126: 13-20.
22. Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
23. Kyrgidis A, Toulis KA,. Denosumab-related osteonecrosis of the jaws. Osteoporos Int 2011; 22: 369-370.
24. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004; 104: 837-844. (Pubitemid 40458815)
25. Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30: 312-321. (Pubitemid 34556102)
26. Kotlarczyk MP, Lassila HC, O'neil CK, et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res 2012; 52: 414-426.
27. Witt-Enderby P, Clafshenkel WP, Kotlarczyk M, et al. Melatonin in bone health. In: Melatonin in the Promotion of Health, Watson RR, ed., CRC Press, Boca Raton, 2011; pp. 261-270.
28. Witt-Enderby PA, Radio NM, Doctor JS, et al. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res 2006; 41: 297-305. (Pubitemid 44498215)
29. Sanchez-Barcelo EJ, Mediavilla MD, Reiter RJ,. Scientific basis for the potential use of melatonin in bone diseases: osteoporosis and adolescent idiopathic scoliosis. J Osteoporos 2010; 830231.
30. Sack RL, Lewy AJ, Erb DL, et al. Human melatonin production decreases with age. J Pineal Res 1986; 3: 379-388. (Pubitemid 17184633)
31. Waldhauser F, Waldhauser M, Lieberman HR, et al. Bioavailability of oral melatonin in humans. Neuroendocrinology 1984; 39: 307-313. (Pubitemid 14031912)
32. Ladizesky MG, Cutrera RA, Boggio V, et al. Effect of melatonin on bone metabolism in ovariectomized rats. Life Sci 2001; 70: 557-565. (Pubitemid 34066523)
33. Uslu S, Uysal A, Oktem G, et al. Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. Anal Quant Cytol Histol 2007; 29: 317-325. (Pubitemid 47608504)
34. Zawilska JB, Skene DJ, Arendt J,. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol Rep 2009; 61: 383-410.
35. Graham C, Cook MR, Gerkovich MM, et al. Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect 2001; 109: 501-507. (Pubitemid 32998808)
36. Conti A, Conconi S, Hertens E, et al. Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res 2000; 28: 193-202. (Pubitemid 30255371)
37. Tan DX, Manchester LC, Reiter RJ, et al. Identification of highly elevated levels of melatonin in bone marrow: its origin and significance. Biochim Biophys Acta 1999; 1472: 206-214. (Pubitemid 29486531)
38. Amstrup AK, Sikjaer T, Mosekilde L, et al. Melatonin and the skeleton. Osteoporos Int 2013; 24: 2919-2927.
39. Hardeland R, Madrid JA, Tan DX, et al. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res 2012; 52: 139-166.
40. Greenspan SL, Dresner-Pollak R, Parker RA, et al. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int 1997; 60: 419-423. (Pubitemid 27183892)
41. Heshmati HM, Riggs BL, Burritt MF, et al. Effects of the circadian variation in serum cortisol on markers of bone turnover and calcium homeostasis in normal postmenopausal women. J Clin Endocrinol Metab 1998; 83: 751-756. (Pubitemid 28496440)
42. Hassager C, Risteli J, Risteli L, et al. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J Bone Miner Res 1992; 7: 1307-1311. (Pubitemid 23000971)
43. Ostrowska Z, Kos-Kudla B, Marek B, et al. Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul 2003; 37: 163-174. (Pubitemid 37413359)
44. Oliveri B, Pellegrini GG, di Gregorio S, et al. Daily rhythm in bone resorption in humans: preliminary observations on the effect of hypoparathyroidism or blindness. Biol Rhythm Res 2008; 39: 13-19.
45. Uebelhart D, Schlemmer A, Johansen JS, et al. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 1991; 72: 367-373. (Pubitemid 21921701)
46. Schlemmer A, Hassager C, Jensen SB, et al. Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 1992; 74: 476-480.
47. Eastell R, Calvo MS, Burritt MF, et al. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J Clin Endocrinol Metab 1992; 74: 487-494.
48. Roth JA, Kim BG, Lin WL, et al. Melatonin promotes osteoblast differentiation and bone formation. J Biol Chem 1999; 274: 22041-22047.
49. Sethi S, Radio NM, Kotlarczyk MP, et al. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res 2010; 49: 222-238.
50. Zhang L, Su P, Xu C, et al. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARgamma expression and enhancing Runx2 expression. J Pineal Res 2010; 49: 364-372.
51. Park KH, Kang JW, Lee EM, et al. Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J Pineal Res 2011; 51: 187-194.
52. Witt-Enderby PA, Slater JP, Johnson NA, et al. Effects on bone by the light/dark cycle and chronic treatment with melatonin and/or hormone replacement therapy in intact female mice. J Pineal Res 2012; 53: 374-384.
53. Fu L, Patel MS, Bradley A, et al. The molecular clock mediates leptin-regulated bone formation. Cell 2005; 122: 803-815. (Pubitemid 41242643)
54. Maronde E, Schilling AF, Seitz S, et al. The clock genes Period 2 and Cryptochrome 2 differentially balance bone formation. PLoS ONE 2010; 5: e11527.
55. Novakova M, Nevsimalova S, Prihodova I, et al. Alteration of the circadian clock in children with Smith-Magenis syndrome. J Clin Endocrinol Metab 2012; 97: E312-E318.
56. Potocki L, Glaze D, Tan DX, et al. Circadian rhythm abnormalities of melatonin in Smith-Magenis syndrome. J Med Genet 2000; 37: 428-433. (Pubitemid 30386734)
57. Moriya T, Hiraishi K, Horie N, et al. Correlative association between circadian expression of mousePer2 gene and the proliferation of the neural stem cells. Neuroscience 2007; 146: 494-498. (Pubitemid 46617071)
58. Gu X, Xing L, Shi G, et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ 2012; 19: 397-405.
59. Gery S, Virk RK, Chumakov K, et al. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene 2007; 26: 7916-7920. (Pubitemid 350262755)
60. Jung-Hynes B, Huang W, Reiter RJ, et al. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res 2010; 49: 60-68.
61. Radio NM, Doctor JS, Witt-Enderby PA,. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res 2006; 40: 332-342.
62. Ducy P, Desbois C, Boyce B, et al. Increased bone formation in osteocalcin-deficient mice. Nature 1996; 382: 448-452. (Pubitemid 26264860)
63. Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999; 13: 1025-1036. (Pubitemid 29200985)
64. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764. (Pubitemid 27516178)
65. Komori T,. Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab 2003; 21: 193-197. (Pubitemid 41184283)
66. Komori T,. Regulation of bone development and maintenance by Runx2. Front Biosci 2008; 13: 898-903. (Pubitemid 351594735)
67. Chen D, Zhao M, Mundy GR,. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-241. (Pubitemid 40136452)
68. Nakamura A, Dohi Y, Akahane M, et al. Osteocalcin secretion as an early marker of in vitro osteogenic differentiation of rat mesenchymal stem cells. Tissue Eng Part C Methods 2009; 15: 169-180.
69. Feskanich D, Hankinson SE, Schernhammer ES,. Nightshift work and fracture risk: the Nurses' Health Study. Osteoporos Int 2009; 20: 537-542.
70. Kim BK, Choi YJ, Chung YS,. Other than daytime working is associated with lower bone mineral density: the Korea national health and nutrition examination survey 2009. Calcif Tissue Int 2013; 93: 495-501.
71. Sadat-Ali M, Al-Habdan I, Al-Othman A,. Adolescent idiopathic scoliosis. Is low melatonin a cause? Joint Bone Spine 2000; 67: 62-64. (Pubitemid 30216940)
72. Moreau A, Wang Da S, Forget S, et al. Melatonin signaling dysfunction in adolescent idiopathic scoliosis. Spine 2004; 29: 1772-1781. (Pubitemid 39079919)
73. Azeddine B, Letellier K, Wang DA S, et al. Molecular determinants of melatonin signaling dysfunction in adolescent idiopathic scoliosis. Clin Orthop Relat Res 2007; 462: 45-52. (Pubitemid 47367842)
74. Yim AP, Yeung HY, Sun G, et al. Abnormal skeletal growth in adolescent idiopathic scoliosis is associated with abnormal quantitative expression of melatonin receptor, MT2. Int J Mol Sci 2013; 14: 6345-6358.
75. Fjelldal PG, Grotmol S, Kryvi H, et al. Pinealectomy induces malformation of the spine and reduces the mechanical strength of the vertebrae in Atlantic salmon, Salmo salar. J Pineal Res 2004; 36: 132-139. (Pubitemid 38250884)
76. Turgut M, Kaplan S, Turgut AT, et al. Morphological, stereological and radiological changes in pinealectomized chicken cervical vertebrae. J Pineal Res 2005; 39: 392-399.
77. Kono H, Machida M, Saito M, et al. Mechanism of osteoporosis in adolescent idiopathic scoliosis: experimental scoliosis in pinealectomized chickens. J Pineal Res 2011; 51: 387-393.
78. Oyama J, Murai I, Kanazawa K, et al. Bipedal ambulation induces experimental scoliosis in C57BL/6J mice with reduced plasma and pineal melatonin levels. J Pineal Res 2006; 40: 219-224. (Pubitemid 43344658)
79. Ostrowska Z, Kos-Kudla B, Nowak M, et al. The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr Regul 2003; 37: 211-224. (Pubitemid 38175991)
80. Machida M, Dubousset J, Imamura Y, et al. Role of melatonin deficiency in the development of scoliosis in pinealectomised chickens. J Bone Joint Surg Br 1995; 77: 134-138.
81. Egermann M, Gerhardt C, Barth A, et al. Pinealectomy affects bone mineral density and structure-an experimental study in sheep. BMC Musculoskelet Disord 2011; 12: 271.
82. Cardinali DP, Ladizesky MG, Boggio V, et al. Melatonin effects on bone: experimental facts and clinical perspectives. J Pineal Res 2003; 34: 81-87. (Pubitemid 36255915)
83. Nakade O, Koyama H, Ariji H, et al. Melatonin stimulates proliferation and type I collagen synthesis in human bone cells in vitro. J Pineal Res 1999; 27: 106-110. (Pubitemid 29440990)
84. Koyama H, Nakade O, Takada Y, et al. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res 2002; 17: 1219-1229. (Pubitemid 34680498)
85. Srivastava S, Toraldo G, Weitzmann MN, et al. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 2001; 276: 8836-8840.
86. Saintier D, Khanine V, Uzan B, et al. Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J Steroid Biochem Mol Biol 2006; 99: 165-173.
87. Robinson LJ, Yaroslavskiy BB, Griswold RD, et al. Estrogen inhibits RANKL-stimulated osteoclastic differentiation of human monocytes through estrogen and RANKL-regulated interaction of estrogen receptor-alpha with BCAR1 and Traf6. Exp Cell Res 2009; 315: 1287-1301.
88. Seifert-Klauss V, Prior JC,. Progesterone and bone: actions promoting bone health in women. J Osteoporos 2010; 2010: 845180.
89. Zaminy A, Ragerdi Kashani I, Barbarestani M, et al. Osteogenic differentiation of rat mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells: melatonin as a differentiation factor. Iran Biomed J 2008; 12: 133-141.
90. Clafshenkel WP, Rutkowski JL, Palchesko RN, et al. A novel calcium aluminate-melatonin scaffold enhances bone regeneration within a calvarial defect. J Pineal Res 2012; 53: 206-218.
91. Satomura K, Tobiume S, Tokuyama R, et al. Melatonin at pharmacological doses enhances human osteoblastic differentiation in vitro and promotes mouse cortical bone formation in vivo. J Pineal Res 2007; 42: 231-239. (Pubitemid 46365059)
92. Liu J, Huang F,. He, HW Melatonin effects on hard tissues: bone and tooth. Int J Mol Sci 2013; 14: 10063-10074.
93. Calvo-Guirado JL, Gãmez-Moreno G, Barone A, et al. Melatonin plus porcine bone on discrete calcium deposit implant surface stimulates osteointegration in dental implants. J Pineal Res 2009; 47: 164-172.
94. Takechi M, Tatehara S, Satomura K, et al. Effect of FGF-2 and melatonin on implant bone healing: a histomorphometric study. J Mater Sci Mater Med 2008; 19: 2949-2952.
95. Munoz F, Lopez-Pena M, Mino N, et al. Topical application of melatonin and growth hormone accelerates bone healing around dental implants in dogs. Clin Implant Dent Relat Res 2012; 14: 226-235.
96. Witt-Enderby P,. Could the fountain of youth be all in your bones? J Oral Implantol 2013; 39: 1-2.
97. Lopez-Martinez F, Olivares Ponce PN, Guerra Rodriguez M, et al. Melatonin: bone metabolism in oral cavity. Int J Dent 2012; 2012: 628406.
98. Zhang L, Zhang J, Ling Y, et al. Sustained release of melatonin from poly (lactic-co-glycolic acid) (PLGA) microspheres to induce osteogenesis of human mesenchymal stem cells in vitro. J Pineal Res 2013; 54: 24-32.
99. Derynck R, Zhang YE,. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584. (Pubitemid 37280136)
100. Miyazono K, Maeda S, Imamura T,. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005; 16: 251-263. (Pubitemid 40910315)
101. Lee MH, Kim YJ, Kim HJ, et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003; 278: 34387-34394.
102. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002; 108: 17-29. (Pubitemid 34137009)
103. Huang W, Yang S, Shao J, et al. Signaling and transcriptional regulation in osteoblast commitment and differentiation. Front Biosci 2007; 12: 3068-3092.
104. Day TF, Guo X, Garrett-Beal L, et al. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8: 739-750. (Pubitemid 40585296)
105. Chau JF, Leong WF, LI B,. Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopathol 2009; 24: 1593-1606.
106. Guo X, Wang XF,. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res 2009; 19: 71-88.
107. Ladizesky MG, Boggio V, Albornoz LE, et al. Melatonin increases oestradiol-induced bone formation in ovariectomized rats. J Pineal Res 2003; 34: 143-151. (Pubitemid 36255923)
108. Clarke B,. Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008; 3 (Suppl 3): S131-S139.
109. Teitelbaum SL,. Osteoclasts: what do they do and how do they do it? Am J Pathol 2007; 170: 427-435. (Pubitemid 47339379)
110. Kearns AE, Khosla S, Kostenuik PJ,. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155-192. (Pubitemid 351519689)
111. Boyle WJ, Simonet WS, Lacey DL,. Osteoclast differentiation and activation. Nature 2003; 423: 337-342. (Pubitemid 40852708)
112. Boyce BF, Xing L,. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007; 9 (Suppl 1): S1.
113. Boyce BF, Xing L,. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 2007; 5: 98-104. (Pubitemid 47577320)
114. Atkins GJ, Kostakis P, Vincent C, et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006; 21: 1339-1349. (Pubitemid 44300040)
115. Rogers A, Eastell R,. REVIEW: circulating osteoprotegerin and receptor activator for nuclear factor kB ligand: clinical utility in metabolic bone assessment. J Clin Endocrinol Metab 2005; 90: 6323-6331. (Pubitemid 41606564)
116. Atkins GJ, Kostakis P, Pan B, et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003; 18: 1088-1098. (Pubitemid 37294947)
117. Ostrowska Z, Kos-Kudla B, Swietochowska E, et al. Assessment of the relationship between dynamic pattern of nighttime levels of melatonin and chosen biochemical markers of bone metabolism in a rat model of postmenopausal osteoporosis. Neuro Endocrinol Lett 2001; 22: 129-136. (Pubitemid 32396391)
118. Histing T, Anton C, Scheuer C, et al. Melatonin impairs fracture healing by suppressing RANKL-mediated bone remodeling. J Surg Res 2012; 173: 83-90.
119. Tan DX, Reiter RJ, Manchester LC, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-197.
120. Tan DX, Chen LD, Poeggeler B, et al. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
121. Cengiz MI, Cengiz S, Wang HL,. Melatonin and oral cavity. Int J Dent 2012; 2012: 491872.
122. Murakami Y, Yuhara K, Takada N, et al. Effect of melatonin on cyclooxygenase-2 expression and nuclear factor-kappa B activation in RAW264.7 macrophage-like cells stimulated with fimbriae of Porphyromonas gingivalis. In Vivo (Brooklyn) 2011; 25: 641-647.
123. Galano A, Tan DX, Reiter RJ,. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
124. Galano A, Tan DX, Reiter RJ,. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J Pineal Res 2013; 54: 245-257.
125. Sanchez-Rodriguez MA, Ruiz-Ramos M, Correa-Munoz E, et al. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord 2007; 8: 124.
126. Fraser JH, Helfrich MH, Wallace HM, et al. Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone 1996; 19: 223-226. (Pubitemid 26302605)
127. Arias-Santiago S, Aneiros-Fernandez J, Arias-Santiago B, et al. MTNR1A receptor expression in normal and pathological human salivary glands. Anticancer Res 2012; 32: 4765-4771.
128. Carrillo-Vico A, Lardone PJ, Naji L, et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 2005; 39: 400-408.
129. Mauriz JL, Collardo PS, Veneroso C,. A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J Pineal Res 2013; 54: 1-14.
130. Liu J, Zhou H, Fan W, et al. Melatonin influences proliferation and differentiation of rat dental papilla cells in vitro and dentine formation in vivo by altering mitochondrial activity. J Pineal Res 2013; 54: 170-178.
131. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36: 1-9. (Pubitemid 38130283)
132. Fischer TW, Kleszczynski K, Hardkop LH,. Melatonin enhances antioxidative enzyme gene expression (CAT, GPx, SOD), prevents their UVR-induced depletion, and protects against formation of DNA damage (8-hydroxy-2′-deoxyguanosine) in ex vivo human skin. J Pineal Res 2013; 54: 303-312.
133. Cutando A, Gomez-Moreno G, Arana C, et al. Melatonin: potential functions in the oral cavity. J Periodontol 2007; 78: 1094-1102.
134. Ray NF, Chan JK, Thamer M, et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35. (Pubitemid 27053608)
135. Wolinsky FD, Fitzgerald JF, Stump TE,. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 1997; 87: 398-403. (Pubitemid 27157452)
136. Iguichi H, Kato KI, Ibayashi H,. Age-dependent reduction in serum melatonin concentrations in healthy human subjects. J Clin Endocrinol Metab 1982; 55: 27-29. (Pubitemid 13250320)
137. Zhou JN, Liu RY, van Heerikhuize J, et al. Alterations in the circadian rhythm of salivary melatonin begin during middle-age. J Pineal Res 2003; 34: 11-16. (Pubitemid 36140352)
138. Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57: 552-558.
139. Brzezinski A,. "Melatonin replacement therapy" for postmenopausal women: is it justified? Menopause 1998; 5: 60-64.
140. Reiter RJ, Tan DX, Manchester LC, et al. Medical implications of melatonin: receptor-mediated and receptor-independent actions. Adv Med Sci 2007; 52: 11-28.
141. Arendt J,. Safety of melatonin in long-term use (?). J Biol Rhythms 1997; 12: 673-681.
142. Markantonis SL, Tsakalozou E, Paraskeva A, et al. Melatonin pharmacokinetics in premenopausal and postmenopausal healthy female volunteers. J Clin Pharmacol 2008; 48: 240-245.
143. Wade A, Downie S,. Prolonged-release melatonin for the treatment of insomnia in patients over 55 years. Expert Opin Investig Drugs 2008; 17: 1567-1572.
144. Cardinali DP, Sirnivasan V, Brzezinski A,. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012; 52: 365-373.
145. Woods NF, Mitchell ES,. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance in women's lives. Am J Med 2005; 118 (Suppl 12B): 14-24.